Article Information
History
- November 10, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Loïc Verlingue1,2,3,*,
- Daphné Morel1,2,4,
- Mickaël Schaeffer3,5,
- Laurent Tanguy3,6,
- Jordane Schmidt7,
- Jean-Christophe Bernhard8,9,
- Bertrand Loubaton3 and
- Dominique Bagnard3,7
- 1Drug Development Department (DITEP), Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94800 Villejuif, France
- 2University Paris-Saclay, France
- 3Adaptherapy, 650 boulevard Gonthier d’Andernach, 67400 Illkirch-Graffenstaden, France
- 4Radiation oncology Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94800 Villejuif, France
- 5Alstats, 2A rue de Bruxelles, Sélestat, France
- 6L. Tanguy 9, rue de verdun 29200 Brest; France
- 7INSERM U1119 BMNST Lab, Labex Medalis, Fédération de Médecine Translationnelle de Strasbourg, Pôle API, 300 boulevard Sébastien Brant, 67412 Illkirch-Graffenstaden, France
- 8Department of Urology – CHU Bordeaux, France
- 9French Research network on Kidney Cancer UroCCR, CHU Bordeaux, France
- ↵*Corresponding authors:
Loic Verlingue, loic.verlingue{at}gustaveroussy.fr
Posted November 10, 2021.
Denoised VEGFR2 expression relates to sunitinib efficacy in advanced Clear Cell Renal Cell Carcinoma
